Question explored with the scientific record
Conversation so far
- 1 Do statins increase life expectancy and by how much?
- 2 Do statins reduce strokes
- 3 What are the best strategies to lower ldl
Answered on this page ↓
What are the best strategies to lower ldl
The short version: the strongest LDL-lowering evidence is for statins, with added benefit from ezetimibe or PCSK9 inhibitors, but the mortality benefit is modest and the data is thin for diet.
Statins are the proven core. A meta-analysis of 14 randomized trials found statins cut all-cause mortality by about 24% (odds ratio 0.76) [2]. The Heart Protection Study in 20,536 high-risk people found simvastatin cut vascular deaths by 17% and major vascular events by 24% over five years [3]. Each 1 mmol/L drop in LDL cuts major vascular events by roughly 22%, based on 60 randomized trials [4].
Adding drugs helps. Ezetimibe or a PCSK9 inhibitor on top of a statin cut cardiovascular events by 18% in a meta-analysis of 100,610 patients, but did not significantly reduce all-cause mortality [1]. PCSK9 inhibitors alone cut LDL by about 50% beyond statins [5]. Inclisiran, a twice-yearly injection, cuts LDL by about 51-52%, but no cardiovascular outcome trial has reported yet [4].
Diet evidence is weaker. Cutting saturated fat lowers LDL by raising LDL receptor numbers, a mechanism shown in a small crossover study [7]. Lean beef in a low-saturated-fat diet lowered LDL modestly [6]. But no retrieved trial shows diet alone cutting heart attacks or death.
| Strategy | LDL reduction | Mortality benefit |
|---|---|---|
| Statins | ~1 mmol/L [3] | ~24% relative [2] |
| Add ezetimibe/PCSK9 | Additional [1] | None shown [1] |
| PCSK9 alone | ~50% [5] | 15% relative [5] |
| Low-saturated-fat diet | Modest [7] | Not studied |
The trials are mostly industry-funded, and the mortality numbers are relative reductions, not absolute. For a healthy person, the absolute benefit is small. My call: statins are the evidence-backed choice; adding ezetimibe or a PCSK9 inhibitor helps high-risk patients; diet helps but is understudied for hard outcomes. Confidence: high for statins, moderate for add-ons, low for diet.
Sources used 7
-
P5015Efficacy of lipid lowering therapy beyond statins to prevent cardiovascular events: A meta-analysis
In a meta-analysis of 9 randomized controlled trials including 100,610 patients, intensified lipid-lowering therapy with ezetimibe or PCSK9 inhibitors added to statins reduced cardiovascular events by 18%, myocardial infarction by 16%, and ischemic stroke by 23%, but did not sig…
DOI: 10.1093/eurheartj/ehz746.0193 -
Clinical Outcomes in Statin Treatment Trials
A comprehensive meta-analysis of randomized statin trials (≥1 year) showing that statin therapy reduces all-cause mortality and major cardiovascular events versus placebo, with variation in effect across statin types and study designs and notable overall applicability across pri…
DOI: 10.1001/archinte.159.15.1793 -
The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]
A large, randomized placebo-controlled trial (Heart Protection Study) in 20,536 high-risk UK adults shows that lowering LDL cholesterol with simvastatin 40 mg daily for about 5 years reduces vascular mortality by ~17% and major vascular events by ~25% without increasing non-vasc…
DOI: 10.1186/1741-7015-3-6 -
Pharmacological management of atherosclerotic cardiovascular disease risk: a narrative of lipid-lowering pharmacotherapy and the LDL-cholesterol dose-response relationship
Statins remain the cornerstone of ASCVD prevention; intensification with ezetimibe, PCSK9 inhibitors, and bempedoic acid improves LDL-C control, while registries show most high-risk patients still miss guideline targets.
DOI: 10.55529/jpdmhd.51.103.115 -
Non–High-Density Lipoprotein Cholesterol and Guidelines for Cholesterol Lowering in Recent History
A narrative review argues that non-HDL cholesterol is a valid, often superior target for cholesterol-lowering therapy and traces guideline evolution from ATP to ACC/AHA, while noting the lack of RCT evidence for treat-to-target and the uncertain general-population benefit.
DOI: 10.1093/labmed/lmz032 -
Beef in an Optimal Lean Diet study: effects on lipids, lipoproteins, and apolipoproteins
This study investigates the effects of a low-saturated fatty acid diet containing lean beef on LDL cholesterol levels compared to a healthy American diet, finding that the inclusion of lean beef can lead to significant reductions in LDL cholesterol and other cardiovascular risk …
DOI: 10.3945/ajcn.111.016261 -
Reducing saturated fat intake is associated with increased levels of LDL receptors on mononuclear cells in healthy men and women
In a randomized three-period crossover study of 25 healthy adults, reducing dietary saturated fat increased LDL receptor abundance on peripheral mononuclear cells and lowered serum LDL-C, suggesting LDL-C reduction is mediated by upregulation of LDL receptors.
DOI: 10.1016/s0022-2275(20)37254-0